Skip to main content
Fig. 1 | Trials

Fig. 1

From: Testing the effects of mass drug administration of azithromycin on mortality and other outcomes among 1–11-month-old infants in Mali (LAKANA): study protocol for a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial

Fig. 1

LAKANA trial design summary. Eligible infants in the villages randomized to (i) placebo (control), receive placebo mixture every 3 months; (ii) 4-dose AZI, receive azithromycin every 3 months; (iii) 2-dose AZI, receive azithromycin twice at a 3-month interval between January and June and placebo twice at a 3-month interval between July and December. AMR, antimicrobial resistance; AZI, azithromycin; LAKANA, Large-scale Assessment of the Key health-promoting Activities of two New mass drug administration regimens with Azithromycin; MDA, mass drug administration

Back to article page

Trials

ISSN: 1745-6215